4-(6-CYANO-5-(2,5-DIOXOPYRROLIDINYL)-7-(4-NITROPHENYL)-7H-PYRANO[2,3-D]THIAZOL-2-YLAMINO)BENZENESULFONAMIDE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	JPIZVJFBBUKIFE-UHFFFAOYSA-N
Smiles	NS(=O)(=O)c1ccc(Nc2nc3OC(=C(C#N)C(c4ccc(cc4)[N+](=O)[O-])c3s2)N5C(=O)CCC5=O)cc1
InChI	InChI=1S/C23H16N6O7S2/c24-11-16-19(12-1-5-14(6-2-12)29(32)33)20-21(36-22(16)28-17(30)9-10-18(28)31)27-23(37-20)26-13-3-7-15(8-4-13)38(25,34)35/h1-8,19H,9-10H2,(H,26,27)(H2,25,34,35)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H16N6O7S2
Molecular Weight	552.54
AlogP	2.69
Hydrogen Bond Acceptor	10.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	6.0
Polar Surface Area	237.91
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	38.0

Assay Description	Organism	Bioactivity
Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay	Homo sapiens	45000.0 nM
Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell surviving fraction at 100 uM after 48 hr by SRB assay	Homo sapiens	0.231
Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell surviving fraction at 50 uM after 48 hr by SRB assay	Homo sapiens	0.342
Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell surviving fraction at 25 uM after 48 hr by SRB assay	Homo sapiens	0.474
Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell surviving fraction at 10 uM after 48 hr by SRB assay	Homo sapiens	0.71

Cross References

Resources	Reference
ChEMBL	CHEMBL2237259
PubChem	76308160

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).